Literature DB >> 2083955

Anti-asialo-GM1 inhibits vaccinia virus infection of murine ovaries: asialo-GM1 as an additional virus receptor?

G Karupiah1, R V Blanden.   

Abstract

The neurovirulent strain of vaccinia virus, VV-WR, or recombinants derived from VV-WR, cause highly productive infection of murine ovaries, but infection could be partially inhibited in vivo using an antiserum to asialo-GM1 (as-GM1). In vitro analysis by flow cytometry revealed that murine ovarian cells expressed a cell surface antigen identical to or cross-reactive with as-GM1. The capacity of VV-WR to infect murine ovaries appears to depend in part upon as-GM1 expression on ovarian cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083955     DOI: 10.1038/icb.1990.46

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  5 in total

1.  Preferential replication of vaccinia virus in the ovaries is independent of immune regulation through IL-10 and TGF-β.

Authors:  Yuan Zhao; Yan Fei Adams; Michael Croft
Journal:  Viral Immunol       Date:  2011-09-29       Impact factor: 2.257

2.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

3.  Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence.

Authors:  R J Jackson; D F Hall; P J Kerr
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

4.  Vaccinia virus infection during murine pregnancy: a new pathogenesis model for vaccinia fetalis.

Authors:  Nicola Benning; Daniel E Hassett
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites.

Authors:  G Karupiah; N Harris
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.